# Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct07371208/  
OnCo record `nct07371208` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer, run by Shanghai Jiao Tong University School of Medicine, now recruiting.

## Summary

Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT07371208 by Shanghai Jiao Tong University School of Medicine, with a registry enrolment figure of 40 participants, started 2025-12-24 and due to reach its primary completion in 2028-08. Interventions recorded: SKB264. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "* Diagnosis: Histologically and/or cytologically confirmed primary triple-negative breast cancer (TNBC) (excluding inflammatory breast cancer), meeting the criteria of tumor size ≥2 cm, clinical lymph node stage cN0 to cN3, and M0 (no distant metastasis)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: ST-A-TN
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07371208
- Phase: 2
- Setting: Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer
- Sponsor: Shanghai Jiao Tong University School of Medicine
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07371208: https://clinicaltrials.gov/study/NCT07371208

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07371208.json